CUMYL-4CN-BINACA (also known as CUMYL-CYBINACA or SGT-78) is an indazole-3-carboxamide based synthetic cannabinoid that has been sold online as a designer drug.[3][4][5][6][7][8] It is a potent agonist for cannabinoid receptors CB1 and CB2, with in vitro EC50 values of 0.58 nM and 6.12 nM, respectively.[9] In mice, CUMYL-4CN-BINACA produces hypothermic and pro-convulsant effects via the CB1 receptor,[9] and anecdotal reports suggest it has an active dose of around 0.1 mg in humans.[10]
Quick Facts Legal status, Identifiers ...
CUMYL-4CN-BINACA![Thumb](//upload.wikimedia.org/wikipedia/commons/thumb/9/9d/CUMYL-4CN-BINACA.svg/140px-CUMYL-4CN-BINACA.svg.png) |
|
Legal status |
|
---|
|
1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide
|
CAS Number | |
---|
PubChem CID | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
CompTox Dashboard (EPA) | |
---|
|
Formula | C22H24N4O |
---|
Molar mass | 360.461 g·mol−1 |
---|
3D model (JSmol) | |
---|
O=C(NC(C)(C)C1=CC=CC=C1)C2=NN(CCCCC#N)C3=C2C=CC=C3
|
InChI=1S/C22H24N4O/c1-22(2,17-11-5-3-6-12-17)24-21(27)20-18-13-7-8-14-19(18)26(25-20)16-10-4-9-15-23/h3,5-8,11-14H,4,9-10,16H2,1-2H3,(H,24,27) Key:JGTSOWOPISVAHG-UHFFFAOYSA-N
|
Close
CUMYL-4CN-BINACA is metabolized to produce cyanide, raising concerns about liver toxicity.[8] There is one reported case of hyperthermia, rhabdomyolysis, and kidney failure associated with its use.[11]
Yeter O (November 2017). "Identification of the Synthetic Cannabinoid 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in Plant Material and Quantification in Post-Mortem Blood Samples". Journal of Analytical Toxicology. 41 (9): 720–728. doi:10.1002/dta.2248. PMID 28977413. Staeheli SN, Poetzsch M, Veloso VP, Bovens M, Bissig C, Steuer AE, Kraemer T (January 2018). "In vitro metabolism of the synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Drug Testing and Analysis. 10 (1): 148–157. doi:10.1002/dta.2298. PMID 28885775. Bovens M, Bissig C, Staeheli SN, Poetzsch M, Pfeiffer B, Kraemer T (December 2017). "Structural characterization of the new synthetic cannabinoids CUMYL-PINACA, 5F-CUMYL-PINACA, CUMYL-4CN-BINACA, 5F-CUMYL-P7AICA and CUMYL-4CN-B7AICA". Forensic Science International. 281: 98–105. doi:10.1016/j.forsciint.2017.10.020. PMID 29125990. Arıkan Ölmez N, Kapucu H, Çallı Altun N, Eren B (January 2018). "Identification of the synthetic cannabinoid N-(2-phenyl-propan-2-yl)-1-(4-cyanobutyl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in a herbal mixture product". Forensic Toxicology. 36 (1): 192–199. doi:10.1007/s11419-017-0372-y. ISSN 1860-8965. S2CID 28058750. Åstrand A, Vikingsson S, Lindstedt D, Thelander G, Gréen H, Kronstrand R, Wohlfarth A (March 2018). "Metabolism study for CUMYL-4CN-BINACA in human hepatocytes and authentic urine specimens: Free cyanide is formed during the main metabolic pathway". Drug Testing and Analysis. 10 (8): 1270–1279. doi:10.1002/dta.2373. PMID 29577658. El Zahran T, Gerona R, Morgan BW, Pomerleau AC (June 2019). "A novel synthetic cannabinoid (Cumyl-4-cyano-BINACA) resulting in hyperthermia, rhabdomyolysis, and renal failure in a 29-year-old patient: it's not meningitis". Clinical Toxicology. 57 (6): 421–422. doi:10.1080/15563650.2018.1534241. PMID 30442067. S2CID 53566116.